Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report ; volume:17 ; number:1 ; day:31 ; month:5 ; year:2023 ; pages:1-7 ; date:12.2023
Journal of medical case reports ; 17, Heft 1 (31.5.2023), 1-7, 12.2023
- Urheber
-
Oki, Yusuke
Nagano, Sho
Ishikawa, Yoichi
Yamada, Takayoshi
Ichimori, Toshiki
Uchida, Kazushige
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-023-03940-y
- URN
-
urn:nbn:de:101:1-2023091208334954490919
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oki, Yusuke
- Nagano, Sho
- Ishikawa, Yoichi
- Yamada, Takayoshi
- Ichimori, Toshiki
- Uchida, Kazushige
- SpringerLink (Online service)
Ähnliche Objekte (12)
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Vedolizumab : chronisch entzündliche Darmerkrankungen: 10 Fälle mit Vedolizumab im Therapiealltag
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Vedolizumab - chronisch-entzündliche Darmerkrankungen (CED): neue Fälle mit Vedolizumab im Therapiealltag
Vedolizumab-Induced Liver Injury
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Vedolizumab : chronisch entzündliche Darmerkrankungen: 10 Fälle mit Vedolizumab im Therapiealltag
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Vedolizumab - chronisch-entzündliche Darmerkrankungen (CED): neue Fälle mit Vedolizumab im Therapiealltag
Vedolizumab-Induced Liver Injury
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Vedolizumab : chronisch entzündliche Darmerkrankungen: 10 Fälle mit Vedolizumab im Therapiealltag
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Vedolizumab - chronisch-entzündliche Darmerkrankungen (CED): neue Fälle mit Vedolizumab im Therapiealltag
Vedolizumab-Induced Liver Injury
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age